Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer

BACKGROUND: The purpose of this work was to determine the efficacy of inhibiting mammalian target of rapamycin (mTOR) in pancreatic cancer preclinical models and translate preclinical observations to the clinic. METHODS: Temsirolimus (20 mg Kg(−1) daily) was administered to freshly generated pancrea...

Descripción completa

Detalles Bibliográficos
Autores principales: Garrido-Laguna, I, Tan, A C, Uson, M, Angenendt, M, Ma, W W, Villaroel, M C, Zhao, M, Rajeshkumar, N V, Jimeno, A, Donehower, R, Iacobuzio-Donahue, C, Barrett, M, Rudek, M A, Rubio-Viqueira, B, Laheru, D, Hidalgo, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938261/
https://www.ncbi.nlm.nih.gov/pubmed/20664591
http://dx.doi.org/10.1038/sj.bjc.6605819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938261/
https://www.ncbi.nlm.nih.gov/pubmed/20664591
http://dx.doi.org/10.1038/sj.bjc.6605819

Ejemplares similares